These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 17699335)

  • 21. Minimize the use of minimization with unequal allocation.
    Proschan M; Brittain E; Kammerman L
    Biometrics; 2011 Sep; 67(3):1135-41. PubMed ID: 21281276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing outcomes on peritoneal and hemodialysis: a case study in the interpretation of observational studies.
    Davies SJ
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):24-30. PubMed ID: 17237887
    [No Abstract]   [Full Text] [Related]  

  • 24. Optimal sample size for a series of pilot trials of new agents.
    Yao TJ; Begg CB; Livingston PO
    Biometrics; 1996 Sep; 52(3):992-1001. PubMed ID: 8805764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical inference for clinical trials with binary responses when there is a shift in patient population.
    Yang LY; Chi Y; Chow SC
    J Biopharm Stat; 2011 May; 21(3):437-52. PubMed ID: 21442518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What does "power of the study" mean? How to compute the power of a study? How to compute the number of subjects needed for a trial?].
    Mélot C
    Rev Mal Respir; 2003 Sep; 20(4):602-3. PubMed ID: 14528163
    [No Abstract]   [Full Text] [Related]  

  • 27. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of the simulation in the clinical investigation].
    Monleón-Getino T
    Med Clin (Barc); 2013 Dec; 141(12):550-5. PubMed ID: 24238627
    [No Abstract]   [Full Text] [Related]  

  • 29. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
    Patel NR; Ankolekar S
    Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis and importance of statistical power and sample size in empirical scientific research].
    Klimek KM
    Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: "Ethics and sample size".
    Halpern SD; Karlawish JH; Berlin JA
    Am J Epidemiol; 2005 Jul; 162(2):195-6; author reply 196. PubMed ID: 15972938
    [No Abstract]   [Full Text] [Related]  

  • 32. Bayesian sample size determination for a clinical trial with correlated continuous and binary outcomes.
    Stamey JD; Natanegara F; Seaman JW
    J Biopharm Stat; 2013; 23(4):790-803. PubMed ID: 23786161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying and assessing the null hypothesis.
    Luft HS
    Health Serv Res; 2000 Feb; 34(6):1265-71. PubMed ID: 10654829
    [No Abstract]   [Full Text] [Related]  

  • 34. A closer look at the distribution of number needed to treat (NNT): a Bayesian approach.
    Thabane L
    Biostatistics; 2003 Jul; 4(3):365-70. PubMed ID: 12925504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A note on special articles on adaptive clinical trial designs.
    Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
    [No Abstract]   [Full Text] [Related]  

  • 36. Sample size computation for two-sample noninferiority log-rank test.
    Jung SH; Kang SJ; McCall LM; Blumenstein B
    J Biopharm Stat; 2005; 15(6):969-79. PubMed ID: 16279355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Bayesian approach for sample size determination in method comparison studies.
    Yin K; Choudhary PK; Varghese D; Goodman SR
    Stat Med; 2008 Jun; 27(13):2273-89. PubMed ID: 17979182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction to discussion papers on draft FDA guidance on adaptive designs.
    Chang M
    J Biopharm Stat; 2010 Nov; 20(6):1113-4. PubMed ID: 21058106
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial: Adaptive designs: appealing in development of therapeutics, and where do controversies lie?
    Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1083-7. PubMed ID: 21058102
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-drug interaction prediction assessment.
    Zhou J; Qin Z; Sara QK; Kim S; Wang Z; Hall SD; Li L
    J Biopharm Stat; 2009 Jul; 19(4):641-57. PubMed ID: 20183431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.